$MO Balance Sheet | Understand Stock

$MO

$73.26 -$0.37 (0.5%) Live

$MO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Assets
Cash and cash equivalents
Receivable from the sale of IQOS System commercialization rights
Receivables
Inventories:
Leaf tobacco
Other raw materials
Work in process
Finished product
Inventory, net
Assets held for sale
Income taxes
Other current assets
Total current assets
Land and land improvements
Buildings and building equipment
Machinery and equipment
Construction in progress
Property, plant and equipment, at cost
Less accumulated depreciation
Property, plant and equipment, net
Goodwill
Other intangible assets, net
Investments in equity securities
Other assets
Total Assets

Liabilities
Short-term borrowings
Current portion of long-term debt
Accounts payable
Accrued liabilities:
Marketing
Settlement charges
Other
Deferred gain from the sale of IQOS System commercialization rights
Dividends payable
Liabilities held for sale
Total current liabilities
Long-term debt
Deferred income taxes
Accrued pension costs
Accrued postretirement health care costs
Other liabilities
Total liabilities

Redeemable noncontrolling interest
Stockholders’ Equity (Deficit)
Common stock, par value $0.33 1/3 per share (2,805,961,317 shares issued)
Additional paid-in capital
Earnings reinvested in the business
Accumulated other comprehensive losses
Cost of repurchased stock (1,136,217,391 shares at December 31, 2026 and 1,131,643,020 shares at December 31, 2025)
Total stockholders’ equity (deficit) attributable to Altria
Noncontrolling interest
Total stockholders’ equity (deficit)
Total Liabilities and Stockholders’ Equity (Deficit)

Comments